All In Biotech

Drug Trial Radar · NCT05639647

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Apr 18, 2023

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants. The study is seeking participants who are: * 9 months to less than 18 years of age * Hospitalized * Suspected/known to have a gram-negative infection * Receiving intravenous (iv, given directly into a vein) antibiotics * Being treated for complicated infections of various body parts that includes the abdomen, urinary tract, blood stream, and lungs. * Participants will receive either ATM-AVI or best available therapy (BAT). * Both therapies will be given through a vein. * Participants with complicated abdominal infections will also receive iv Metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - Participants on ATM-AVI treatment who have anaerobic infections will also receive iv MTZ at the study doctor's discretion. * The iv dose of ATM-AVI will be based on the participant's weight and kidney function. * The study doctor will determine the iv dose of BAT. * During the first 2 study days, participants on ATM-AVI therapy will have 5 blood draws in small quantities. * Starting on day 4, the study doctor will decide if participants may be switched to oral therapy. * Participants will receive a maximum of 14 days of ATM-AVI treatment. * After discharge from the hospital, 1 study visit may be required. * Depending on the participant's response, the study duration will be from 33 to 50 days. * The investigator will contact participants by phone 28 to 35 days after the last study treatment to check participants health status.

Conditions

  • Gram-negative Bacterial Infections

Interventions

  • ATM-AVIDrug

    A drug specifically designed to treat resistant gam-negative bacterial infections

  • BATDrug

    BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Predicted Plasma Concentration (Cmax) of ATM and AVITime frame: Up to 15 Days
  2. Minimum Predicted Trough Plasma Concentration (Cmin) of ATM and AVITime frame: Up to 15 Days
  3. Area under the Concentration-Time Curve (AUC) of ATM-AVITime frame: Up to 15 Days
  4. Plasma Decay Half-Life (t1/2)Time frame: Up to 15 Days
  5. Apparent Clearance (CL)Time frame: Up to 15 Days
  6. Proportion of Participants reporting Adverse Events (AE)Time frame: Baseline up to Day 50
  7. Proportion of Participants reporting Serious Adverse Events (SAE)Time frame: Baseline up to Day 50
  8. Proportion of Participants reporting AEs leading to discontinuationTime frame: Baseline up to Day 50
  9. Proportion of Participants reporting AEs resulting in deathTime frame: Baseline up to Day 50
  10. Proportion of Participants reporting liver injury and acute kidney injury of ATM-AVI relative to Best Available Therapy (BAT)Time frame: Baseline up to Day 50

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • Weill Cornell Medicine-New York Presbyterian Hospital

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Shanghai Children's Medical Center

    Shanghai, China · Recruiting

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Recruiting

  • University General Hospital of Heraklion

    Heraklion, Irakleío, Greece · Recruiting

  • Ippokrateio General Hospital of Thessaloniki

    Thessaloniki, Kentrikí Makedonía, Greece · Recruiting

  • Semmelweis Egyetem

    Budapest, Hungary · Recruiting

  • RajaRajeswari Medical College and Hospital

    Bangalore, Karnataka, India · Recruiting

  • Medanta Hospital Lucknow

    Lucknow, Uttar Pradesh, India · Recruiting

  • Institute of Child Health

    Kolkata, West Bengal, India · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona [barcelona], Spain · Recruiting

  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona [barcelona], Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, Taiwan · Recruiting

  • Hsinchu Municipal Mackay Children's Hospital

    Hsinchu, Hsinchu, Taiwan · Recruiting

  • Cukurova Universty

    Sarçam, Adana, Turkey (Türkiye) · Active not recruiting

  • Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi

    Istanbul, İ̇stanbul, Turkey (Türkiye) · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.